NASDAQ: NNNNAnbio Biotechnology Stock
$15.59-0.85 (-5.17%)
Updated Jun 12, 2026
NNNN Price
$15.59
Fair Value Price
$0.46
Market Cap
$2.24B
52 Week Low
$8.60
52 Week High
$55.65
P/E
106.05x
P/B
74.39x
P/S
151.87x
PEG
N/A
Dividend Yield
N/A
Revenue
$8.65M
Earnings
$6.40M
Gross Margin
87.2%
Operating Margin
74.06%
Profit Margin
74.1%
Debt to Equity
0
Operating Cash Flow
-$7M
Beta
0.31
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
NNNN Overview
Anbio Biotechnology, established in 2021 and based in Frankfurt am Main, Germany, operates as a global supplier of in vitro diagnostics (IVD) products. The company's international footprint covers regions such as the European Union, Asia Pacific, North America, South America, and Africa. Their product range features various diagnostic solutions, including rapid antigen tests for SARS-CoV-2 (both individual and combined with influenza A/B). Anbio also develops and manufactures products leveraging advanced technologies like lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification (LAMP), chemiluminescence immunoassay (CLIA), and reverse-transcription polymerase chain reaction (RT-PCR). These offerings cater to a wide array of markets, including over-the-counter sales, point-of-care testing, and traditional laboratory settings.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine NNNN's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Medical
Industry Rating
B
NNNN
Ranked#20 of 42
Ranked#20 of 42
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $9.14 | A | |
| $142.20 | B | |
| $15.08 | B |
Be the first to know about important NNNN news, forecast changes, insider trades & much more!
NNNN News
Overview
Due Diligence Score
–
Industry Average (30)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how NNNN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
NNNN ($15.59) is overvalued by 3,325.06% relative to our estimate of its Fair Value price of $0.46 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
NNNN ($15.59) is not significantly undervalued (3,325.06%) relative to our estimate of its Fair Value price of $0.46 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
NNNN was unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more NNNN due diligence checks available for Premium users.
Valuation
NNNN fair value
Fair Value of NNNN stock based on Discounted Cash Flow (DCF)
Price
$15.59
Fair Value
$0.46
Overvalued by
3,325.06%
NNNN ($15.59) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
NNNN ($15.59) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
NNNN was unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
NNNN price to earnings (PE)
For valuing profitable companies with steady earnings
Company
106.05x
Industry
42.82x
Market
14.15x
NNNN is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
NNNN is poor value based... subscribe to Premium to read more.
P/E vs Market Valuation
NNNN price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
74.39x
Industry
3.19x
NNNN is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
NNNN's financial health
Profit margin
Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
NNNN's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
NNNN's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$30.2M
Liabilities
$87.8k
Debt to equity
0
NNNN's short-term assets ($30.24M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
NNNN's short-term assets ($30.24M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
NNNN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
NNNN's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
NNNN vs Medical Stocks
Anbio Biotechnology Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.